Literature DB >> 33229627

DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas.

Tingyu Liang1, Xingang Zhou2, Peiliang Li1, Gan You3, Fang Wang1, Peng Wang2, Enshan Feng1.   

Abstract

BACKGROUND: Malignant glioma is the most common form of primary malignant brain cancer. Heterogeneity is the hallmark of glioma. DAZ-interacting zinc finger 3 (DZIP3), acts as an RNA-binding RING-type ubiquitin ligase; however, its function in glioma is yet unclear.
RESULTS: The DZIP3 expression was related to the World Health Organization (WHO) grade and isocitrate dehydrogenase 1(IDH1) status, as well as the clinical outcome. Malignant cases exhibit lower DZIP3 expression. DZIP3 was an independent predictive factor of good prognosis in all grade and lower grade gliomas (p < 0.0001). Gene enrichment analysis and immunohistochemistry indicated that DZIP3 affected the biological behavior of glioma through the angiogenesis pathway. Moreover, based on DZIP3 expression, IDH1 wild-type lower-grade gliomas could be divided into two groups with different survival time.
CONCLUSION: In conclusion, the loss of DZIP3 may be involved in the mechanism of angiogenesis in the invasive biological process of glioma. These findings laid an understanding of DZIP3-specific clinical features in glioma.
METHODS: A total of 325 glioma patients from the Chinese Glioma Genome Atlas (CGGA) RNA-seq cohort comprised the training cohort, while 265 patients from the GSE 16011 array cohort formed the validation cohort. The mRNA expression of DZIP3 and clinical characteristics was assessed. DZIP3 protein expression and microvessel density (MVD) were evaluated by immunohistochemistry (IHC).

Entities:  

Keywords:  DZIP3; IDH1 wild-type; glioma; survival time

Mesh:

Substances:

Year:  2020        PMID: 33229627      PMCID: PMC7803555          DOI: 10.18632/aging.103817

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  29 in total

1.  IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.

Authors:  Felipe J Núñez; Flor M Mendez; Padma Kadiyala; Mahmoud S Alghamri; Masha G Savelieff; Maria B Garcia-Fabiani; Santiago Haase; Carl Koschmann; Anda-Alexandra Calinescu; Neha Kamran; Meghna Saxena; Rohin Patel; Stephen Carney; Marissa Z Guo; Marta Edwards; Mats Ljungman; Tingting Qin; Maureen A Sartor; Rebecca Tagett; Sriram Venneti; Jacqueline Brosnan-Cashman; Alan Meeker; Vera Gorbunova; Lili Zhao; Daniel M Kremer; Li Zhang; Costas A Lyssiotis; Lindsey Jones; Cameron J Herting; James L Ross; Dolores Hambardzumyan; Shawn Hervey-Jumper; Maria E Figueroa; Pedro R Lowenstein; Maria G Castro
Journal:  Sci Transl Med       Date:  2019-02-13       Impact factor: 17.956

2.  Generation of Rat Monoclonal Antibodies Specific for DZIP3.

Authors:  Daisuke Oikawa; Masayuki Shiota; Fuminori Tokunaga; Hideki Wanibuchi
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2018-05-29

3.  Adult IDH wild-type lower-grade gliomas should be further stratified.

Authors:  Abudumijit Aibaidula; Aden Ka-Yin Chan; Zhifeng Shi; Yanxi Li; Ruiqi Zhang; Rui Yang; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Yu Yao; Liangfu Zhou; Jinsong Wu; Hong Chen; Ho-Keung Ng
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

Review 4.  EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.

Authors:  Stefanie Keller; Mirko H H Schmidt
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

5.  DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.

Authors:  H Binder; E Willscher; H Loeffler-Wirth; L Hopp; D T W Jones; S M Pfister; M Kreuz; D Gramatzki; E Fortenbacher; B Hentschel; M Tatagiba; U Herrlinger; H Vatter; J Matschke; M Westphal; D Krex; G Schackert; J C Tonn; U Schlegel; H-J Steiger; W Wick; R G Weber; M Weller; M Loeffler
Journal:  Acta Neuropathol Commun       Date:  2019-04-25       Impact factor: 7.801

6.  Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status.

Authors:  Ning Wang; Shu-Yi Xie; Hui-Ming Liu; Guo-Quan Chen; Wei-Dong Zhang
Journal:  Transl Oncol       Date:  2019-03-15       Impact factor: 4.243

7.  Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.

Authors:  Enshan Feng; Tingyu Liang; Xiaoyong Wang; Juan Du; Kai Tang; Xiaoxuan Wang; Fang Wang; Gan You
Journal:  J Neuroinflammation       Date:  2019-02-12       Impact factor: 8.322

8.  IDH mutation-specific radiomic signature in lower-grade gliomas.

Authors:  Xing Liu; Yiming Li; Shaowu Li; Xing Fan; Zhiyan Sun; Zhengyi Yang; Kai Wang; Zhong Zhang; Tao Jiang; Yong Liu; Lei Wang; Yinyan Wang
Journal:  Aging (Albany NY)       Date:  2019-01-29       Impact factor: 5.682

9.  Dzip3 regulates developmental genes in mouse embryonic stem cells by reorganizing 3D chromatin conformation.

Authors:  Daishi Inoue; Hitoshi Aihara; Tatsuharu Sato; Hirofumi Mizusaki; Masamichi Doiguchi; Miki Higashi; Yuko Imamura; Mitsuhiro Yoneda; Takayuki Miyanishi; Satoshi Fujii; Akihiko Okuda; Takeya Nakagawa; Takashi Ito
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

10.  IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Authors:  Ryohei Otani; Takeo Uzuka; Fumi Higuchi; Hadzki Matsuda; Masashi Nomura; Shota Tanaka; Akitake Mukasa; Koichi Ichimura; Phyo Kim; Keisuke Ueki
Journal:  Cancer Sci       Date:  2018-06-15       Impact factor: 6.716

View more
  2 in total

1.  DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis.

Authors:  Yuan-Jie Liu; Jie-Pin Li; Shu-Hong Zeng; Mei Han; Shen-Lin Liu; Xi Zou
Journal:  Pharmgenomics Pers Med       Date:  2021-09-16

2.  Construction of immune cell infiltration protein network based on clinical low grade glioma cases.

Authors:  Wei Jiang; Zijian He; Weizhong Jiang; Jiarui Du; Lutao Yuan; Cong Luo; Xiang Li; Fulin Xu
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.